Wall Street brokerages expect Cytokinetics, Inc. (NASDAQ:CYTK) to post ($0.71) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Cytokinetics’ earnings. The lowest EPS estimate is ($0.93) and the highest is ($0.33). Cytokinetics posted earnings per share of $0.16 in the same quarter last year, which would indicate a negative year-over-year growth rate of 543.8%. The company is scheduled to announce its next earnings results on Thursday, February 15th.
On average, analysts expect that Cytokinetics will report full-year earnings of ($2.40) per share for the current financial year, with EPS estimates ranging from ($2.76) to ($2.14). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.87) per share, with EPS estimates ranging from ($2.63) to ($1.11). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Cytokinetics.
Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.64) by $0.04. The firm had revenue of $6.18 million during the quarter, compared to the consensus estimate of $5.35 million. Cytokinetics had a negative return on equity of 62.64% and a negative net margin of 172.27%.
Several brokerages have recently commented on CYTK. Morgan Stanley reiterated an “overweight” rating and set a $25.00 target price (up from $24.00) on shares of Cytokinetics in a research note on Friday, October 6th. Seaport Global Securities reiterated a “buy” rating and set a $24.00 target price on shares of Cytokinetics in a research note on Friday, October 6th. Cantor Fitzgerald reiterated a “buy” rating and set a $21.00 target price on shares of Cytokinetics in a research note on Tuesday, September 26th. HC Wainwright reiterated a “buy” rating and set a $26.00 target price on shares of Cytokinetics in a research note on Wednesday, September 20th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Cytokinetics in a research note on Sunday, October 29th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $17.64.
Cytokinetics (NASDAQ CYTK) traded down $0.15 during mid-day trading on Thursday, reaching $8.80. The company’s stock had a trading volume of 335,873 shares, compared to its average volume of 289,172. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.60 and a current ratio of 7.60. Cytokinetics has a 12-month low of $7.00 and a 12-month high of $17.20. The company has a market capitalization of $472.84, a P/E ratio of -5.30 and a beta of 1.61.
In related news, EVP Fady Ibraham Malik sold 7,321 shares of the business’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $13.39, for a total value of $98,028.19. Following the completion of the sale, the executive vice president now directly owns 47,540 shares in the company, valued at approximately $636,560.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert I. Blum sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $13.51, for a total value of $67,550.00. Following the completion of the sale, the chief executive officer now owns 70,180 shares of the company’s stock, valued at $948,131.80. The disclosure for this sale can be found here. Insiders sold a total of 16,581 shares of company stock valued at $220,703 over the last 90 days. 7.20% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CYTK. Birchview Capital LP acquired a new position in Cytokinetics in the 3rd quarter valued at $145,000. Piedmont Investment Advisors LLC acquired a new position in Cytokinetics in the 3rd quarter valued at $159,000. BNP Paribas Arbitrage SA raised its holdings in Cytokinetics by 4,464.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,328 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 13,036 shares in the last quarter. SG Americas Securities LLC raised its holdings in Cytokinetics by 73.3% in the 2nd quarter. SG Americas Securities LLC now owns 14,306 shares of the biopharmaceutical company’s stock valued at $173,000 after acquiring an additional 6,052 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Cytokinetics in the 2nd quarter valued at $177,000. Institutional investors and hedge funds own 73.61% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/11/zacks-brokerages-anticipate-cytokinetics-inc-cytk-to-announce-0-71-eps.html.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.
Get a free copy of the Zacks research report on Cytokinetics (CYTK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.